Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROL vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Treatment of acute angina pectoris,Prophylaxis of angina pectoris (pre-exertional use),Management of acute myocardial infarction (FDA-approved),Congestive heart failure (off-label, in acute settings)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
1-4 minutes for nitroglycerin; clinical effect disappears within 30-60 minutes due to rapid metabolism and redistribution.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Primarily metabolized by nitrate reductase in the liver; also undergoes denitration by glutathione-dependent organic nitrate reductase and by hemoglobin in red blood cells.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal: minimal, <1% unchanged; extensive metabolism by liver, metabolites excreted renally. Biliary/fecal: negligible.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Approximately 60% bound to albumin.
Isosorbide mononitrate is less than 5% bound to plasma proteins.
3.3 L/kg, indicating extensive distribution into tissues.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: ~40-60% (first-pass metabolism); Oral: <10% due to high first-pass; Transdermal: ~20-30% with continuous delivery; Intravenous: 100%.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No specific adjustment for GFR; monitor for hypotension and methemoglobinemia in severe impairment. Use with caution in dialysis patients.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate carefully. Child-Pugh C: Avoid use or use with extreme caution, consider alternative therapy.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Sublingual/translingual: 5 mcg/kg/dose every 5-10 minutes as needed for acute angina, max 4 doses. IV: Start 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min, max 5 mcg/kg/min. Not recommended for neonates due to risk of methemoglobinemia.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Start at low end of adult dose (sublingual 0.3 mg, transdermal 0.2 mg/hr, IV 5 mcg/min). Titrate slowly due to increased sensitivity and risk of hypotension. Monitor for orthostatic hypotension.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Contraindicated in patients with erectile dysfunction who are using phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Risk of severe hypotension and syncope, especially in volume-depleted patients or those with low systolic blood pressure; tolerance and cross-tolerance with other nitrates may develop; abrupt cessation may precipitate angina; caution in patients with hypertrophic obstructive cardiomyopathy.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin or any component; severe anemia; increased intracranial pressure (e.g., head trauma, cerebral hemorrhage); concurrent use with PDE-5 inhibitors; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Alcohol can exacerbate hypotensive effects and should be avoided. No specific food restrictions; however, high-fat meals may delay sublingual absorption but not clinically significant.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin has been shown to be embryotoxic in rats and rabbits at doses 20 times the human dose. Use in first trimester only if clearly needed. During second and third trimesters, may be used for management of preterm labor or pregnancy-induced hypertension, but monitor for maternal hypotension and fetal bradycardia.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Not known if nitroglycerin is excreted in human milk. M/P ratio not available. Because of potential for serious adverse reactions in nursing infants, discontinue nursing or discontinue drug, taking into account importance of drug to mother. Use with caution if breastfeeding; avoid high doses or continuous exposure.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No specific dose adjustments recommended for pregnancy-related PK changes. However, increased plasma volume and cardiac output in pregnancy may require higher doses for therapeutic effect. Start at lowest effective dose and titrate based on clinical response and blood pressure. For intravenous use in pregnancy, standard non-pregnant doses may be used but with careful titration.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Nitrol (nitroglycerin) is a potent vasodilator used primarily for angina pectoris. Sublingual tablets should be administered at first sign of attack; patient should be sitting to prevent syncope from hypotension. If pain persists after 3 doses 5 minutes apart, seek emergency care. Tolerance develops with sustained use; avoid long-acting formulations for acute episodes. Monitor for orthostatic hypotension and headache, common side effects. Contraindicated with concurrent use of PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Take sublingual nitroglycerin at the first sign of chest pain; do not swallow. Place tablet under tongue and allow to dissolve.,Sit down before taking to avoid fainting due to drop in blood pressure.,If pain is not relieved after 1 dose, take a second dose after 5 minutes. If not relieved after 3 doses, call 911 immediately.,Store tablets in original glass container, tightly closed, away from light and heat. Replace every 6 months as potency decreases.,Avoid alcohol and erectile dysfunction drugs (e.g., Viagra, Cialis) as they can cause severe hypotension.,Common side effects include headache, dizziness, and flushing. Headache may indicate effectiveness.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROL vs MONOKET, answered by our medical review team.
NITROL is a Nitrate Vasodilator that works by NITROL (nitroglycerin) is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROL and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROL is: Sublingual: 0.3-0.6 mg every 5 minutes as needed for angina, up to 3 doses in 15 minutes. Translingual spray: 1-2 sprays (0.4 mg/spray) under tongue every 5 minutes as needed, max 3 doses in 15 minutes. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours. Intravenous: Initial 5 mcg/min, titrate by 5 mcg/min every 3-5 minutes until response, usual range 10-200 mcg/min.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROL and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROL is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, nitroglycerin has been shown to be embryotoxic in rats and rabbits at doses 20 times the human d. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.